The research findings, which include data on the physical activities of patients treated with JW Pharmaceutical’s hemophilia A treatment ‘Hemlibra (emicizumab)’ and their safety profile, have been published in the International Journal of Hematology (Int J Hematol).

Hemlibra is an innovative new drug that mimics the function of blood coagulation factor VIII, which is usually deficient in patients with hemophilia. It is unique in that it can be used to treat hemophilia A in both patients with antibodies and those who are resistant to existing treatments (factor VIII drugs). A single subcutaneous injection of Hemlibra can yield a lasting preventive effect for up to four weeks. Last May, reimbur